Boston Trust Walden Increases Stake in Chemed Corporation

Summary

Boston Trust Walden Company increased its holdings in Chemed Corporation by 1.7% in the first quarter, now possessing 246,351 shares valued at $151.6 million. Chemed’s stock opened at $546.00, and the company has a market capitalization of $7.99 billion. Chemed reported first-quarter earnings per share of $5.63, exceeding expectations, and announced a quarterly dividend of $0.50. Analysts have upgraded Chemed’s rating and set new price targets, forecasting an annual earnings per share of $21.43.Market Beat

Impact Analysis

This is a company-level event affecting Chemed Corporation directly. Boston Trust Walden’s increase in shares signals positive investor sentiment and confidence in Chemed’s future performance, especially after exceeding earnings expectations. The increased earnings per share suggests robust financial health, leading to analyst upgrades and optimistic price targets. As a result, Chemed’s stock may see increased demand, pushing the price higher. Investors might consider opportunities in Chemed’s stock, benefitting from anticipated growth and dividends. However, risks include potential volatility post-earnings announcement and competition within the industry.Market Beat